文献速递前列腺癌

中危前列腺癌十年疗效:根治性前列腺切除术对比外照射放疗与近距离放疗

Ten-Year Treatment Outcomes of Radical Prostatectomy Vs External Beam Radiation Therapy Vs Brachytherapy for 1503 Patients With Intermediate-risk Prostate Cancer.
PubMed 文献 · Urology · 2019-11-05

该回顾性倾向评分匹配研究纳入1503例中危前列腺癌患者,比较根治性前列腺切除术、外照射放疗与碘-125近距离放疗的10年肿瘤学结局。结果显示近距离放疗调整后10年无生化失败率优于根治性手术和外照射放疗,而转移-free生存与前列腺癌特异性生存在三组间无显著差异。

要点

  • 近距离放疗调整后10年无生化失败率80.2%,优于根治性手术57.1%和外照射放疗57.0%。
  • 三组调整后转移-free生存与前列腺癌特异性生存无显著差异。
  • 近距离放疗单用或联合补充外照射是中危前列腺癌的合理选择。

核心结论

  • 碘-125近距离放疗单用或联合补充外照射治疗中危前列腺癌,可获得与根治性前列腺切除术及外照射放疗等效的转移-free生存和前列腺癌特异性生存。

研究设计与样本

  • 回顾性倾向评分匹配分析,纳入2004至2007年治疗的1503例中危前列腺癌患者。

主要发现

  • 中位随访时间:根治性手术10.0年,外照射放疗9.6年,近距离放疗9.8年。
  • 新辅助雄激素剥夺治疗比例:根治性手术0.6%,外照射放疗58.9%,近距离放疗12.7%,P <.0001。
  • 仅14%的近距离放疗患者接受补充外照射。
  • 调整后10年无生化失败率:近距离放疗80.2%,根治性手术57.1%,外照射放疗57.0%,P = .0003。
  • 不良中危亚组分析亦显示近距离放疗无生化失败率更优,P <.0001;调整年龄和Charlson合并症指数后,转移-free生存和前列腺癌特异性生存无显著差异。

关键数值与推荐

  • 生化失败定义:根治性手术采用美国泌尿外科学会定义,外照射放疗和近距离放疗采用Phoenix定义。

临床怎么用

  • 中危前列腺癌患者选择治疗方案时,碘-125近距离放疗可作为根治性手术和外照射放疗之外的合理选项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare 10-year oncologic treatment outcomes of radical prostatectomy (RP) vs external beam radiation therapy (EBRT) vs brachytherapy (BT) for patients with intermediate-risk prostate cancer (IRPC). METHODS: A retrospective analysis using propensity score matching was performed on 1503 IRPC patients who underwent treatment from 2004 to 2007. Eight hundred and nineteen underwent RP, 574 underwent EBRT to a median dose of 75.3 Gray, and 110 underwent BT using Iodine-125. Biochemical failure was defined by the American Urological Association definition of failure for RP, and the Phoenix definition for EBRT and BT. RESULTS: Median follow-up was 10.0 years for RP, 9.6 for EBRT, and 9.8 for BT. Neoadjuvant androgen deprivation therapy was given in 0.6% of RP, 58.9% of EBRT, and 12.7% of BT patients, P <.0001. Only 14% of BT received supplemental external radiation. The adjusted 10-year freedom from biochemical failure was 80.2% for BT vs 57.1% for RP vs 57.0% for EBRT, P = .0003. Subset analysis of unfavorable IRPC also showed improved freedom from biochemical failure with BT, P <.0001. There were no significant differences in metastases-free survival or prostate cancer-specific survival after adjusting for age and Charlson comorbidity index. CONCLUSION: BT using Iodine-125, used alone or in combination with supplemental external radiation, is a reasonable treatment option for IRPC patients, yielding equivalent rates of metastases-free survival and prostate cancer-specific survival.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Goy BW, Burchette R, Soper MS, et al. Ten-Year Treatment Outcomes of Radical Prostatectomy Vs External Beam Radiation Therapy Vs Brachytherapy for 1503 Patients With Intermediate-risk Prostate Cancer. Urology. 2019. PMID: 31704459. doi:10.1016/j.urology.2019.09.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。